Skip to main content
. Author manuscript; available in PMC: 2024 Jul 22.
Published in final edited form as: Vaccine. 2022 Nov 1;40(50):7176–7181. doi: 10.1016/j.vaccine.2022.10.031

Fig. 2. Distribution of predicted impact for vaccines with 30%, 50%, or 70% efficacy and 2, 5, or 8-year duration under low (20%) or high (50%) and vaccine coverage assuming a baseline prevalence of 1.125% in women and 0.75% in men.

Fig. 2.

Below each panel are the minimum, 25th percentile, median, 75th percentile, and maximum predicted impact at each coverage level.